Title |
Bone Health in Men with Prostate Cancer: Review Article
|
---|---|
Published in |
Current Osteoporosis Reports, November 2019
|
DOI | 10.1007/s11914-019-00536-8 |
Pubmed ID | |
Authors |
Salma A M El Badri, Abdulazeez Salawu, Janet E Brown |
Abstract |
The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment-induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required. The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment. It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 56 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 18% |
Student > Bachelor | 7 | 13% |
Student > Master | 7 | 13% |
Researcher | 4 | 7% |
Other | 3 | 5% |
Other | 6 | 11% |
Unknown | 19 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 30% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
Immunology and Microbiology | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Engineering | 2 | 4% |
Other | 5 | 9% |
Unknown | 22 | 39% |